"Murtha, Andrew J." - Selaus tekijän mukaan TUNICRIS-julkaisut

Viitteet 1-2 / 2

    • Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer 

      Vandekerkhove, Gillian; Lavoie, Jean Michel; Annala, Matti; Murtha, Andrew J.; Sundahl, Nora; Walz, Simon; Sano, Takeshi; Taavitsainen, Sinja; Ritch, Elie; Fazli, Ladan; Hurtado-Coll, Antonio; Wang, Gang; Nykter, Matti; Black, Peter C.; Todenhöfer, Tilman; Ost, Piet; Gibb, Ewan A.; Chi, Kim N.; Eigl, Bernhard J.; Wyatt, Alexander W. (2021)
      article
      Molecular stratification can improve the management of advanced cancers, but requires relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a recent expansion of treatment options and its ...

    • Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer 

      Fonseca, Nicolette M.; Maurice-Dror, Corinne; Herberts, Cameron; Tu, Wilson; Fan, William; Murtha, Andrew J.; Kollmannsberger, Catarina; Kwan, Edmond M.; Parekh, Karan; Schönlau, Elena; Bernales, Cecily Q.; Donnellan, Gráinne; Ng, Sarah W.S.; Sumiyoshi, Takayuki; Vergidis, Joanna; Noonan, Krista; Finch, Daygen L.; Zulfiqar, Muhammad; Miller, Stacy; Parimi, Sunil; Lavoie, Jean Michel; Hardy, Edward; Soleimani, Maryam; Nappi, Lucia; Eigl, Bernhard J.; Kollmannsberger, Christian; Taavitsainen, Sinja; Nykter, Matti; Tolmeijer, Sofie H.; Boerrigter, Emmy; Mehra, Niven; van Erp, Nielka P.; De Laere, Bram; Lindberg, Johan; Grönberg, Henrik; Khalaf, Daniel J.; Annala, Matti; Chi, Kim N.; Wyatt, Alexander W. (2024)
      article
      No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility ...